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PTEN Is Associated With Worse Local Control in Early Stage
Supraglottic Laryngeal Cancer Treated With Radiotherapy
Leonie Bruine de Bruin, MD ; Jan E. Wachters, MD; Michiel L. Schrijvers, MD, PhD;
Lorian Slagter-Menkema, BSc; Mirjam F. Mastik, BSc; Johannes A. Langendijk, MD, PhD;
Jacqueline E. van der Wal, MD, PhD‡; Ed Schuuring, PhD†; Bernard F. A. M. van der Laan, MD, PhD†
Objectives: The aim of this study was to establish the prognostic value of the epidermal growth factor receptor (EGFR)
and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression on local control in patients with early
stage supraglottic laryngeal squamous cell carcinoma (LSCC) treated with radiotherapy only.
Study design: Retrospective cohort study.
Methods: Immunohistochemical staining for EGFR and PTEN was performed on pretreatment biopsies of a selected well-
deﬁned homogeneous group of 52 patients with T1–T2 supraglottic LSCC treated with radiotherapy between 1990 and 2008.
Kaplan–Meier analysis and univariate and multivariate Cox Regression analyses were performed to correlate clinical data and
expression levels of EGFR and PTEN with local control.
Results: Kaplan–Meier survival analysis and Cox Regression analysis showed a signiﬁcant association between PTEN
expression and local control (hazard ratio [HR] = 3.26, 95% conﬁdence interval [CI] = 1.14–9.33, P = .027) and between lymph
node status and local control (HR = 3.60, 95% CI = 1.26–10.31, P = .017). Both were independent prognostic factors in a multi-
variate analysis (HR = 3.28, 95% CI = 1.14–9.39, P = .027 and HR = 3.62, 95% CI = 1.26–10.37, P = .017, respectively). There
was no signiﬁcant association between EGFR expression and local control (HR = 1.32, 95% CI = 1.17–10.14, P = .79).
Conclusion: This study showed an association between both high PTEN expression and the presence of lymph node
metastasis and deteriorated local control in early stage supraglottic LSCC treated with radiotherapy.
Key Words: EGFR, PTEN, laryngeal squamous cell carcinoma, radiotherapy, local control.
Level of Evidence: NA
INTRODUCTION
Most early stage (T1–T2) laryngeal squamous cell
carcinomas (LSCC) are treated with radiotherapy only. The
5-year local control rates after radiotherapy vary between
43%–95% and 41%–58% for glottic and supraglottic T1–T2
LSCC, respectively.1,2 Currently, besides sublocation and
stage of the primary tumor, no suitablemarkers are available
for predicting prognosis. Cell biological markersmay be help-
ful to select patients who may beneﬁt from additional treat-
ment and identify newpotential targets for therapy.3
In cancer, activation of signaling pathways, including
the PI3K/AKTantiapoptotic and proliferation pathway, could
contribute to tumorigenesis and hence a worse prognosis.4–6
The PI3K/AKT pathway can be triggered by activation of the
epidermal growth factor receptor (EGFR), a transmembrane
glycoprotein consisting of an extracellular ligand binding
domain, a transmembrane region, and an intracellular tyro-
sine kinase domain. Upon binding of the speciﬁc ligand, phos-
phorylation of the intracellular tyrosine kinase occurs,
activating the PI3K/AKT pathway.4,7 More than 80% of the
head and neck squamous cell carcinomas (HNSCC) show
EGFR overexpression.8 It has been suggested that EGFR
plays an important role in response to radiotherapy, resulting
in decreased local control.9–12 The last decade EGFR has
become an important target in cancer therapy with the use
of cetuximab, an anti-EGFR antibody.4 In HNSCC, the use
of cetuximab is approved by the FDA in combination with
radiotherapy for patients with locally advanced non-
metastatic HNSCC in case chemoradiation is not feasi-
ble.13 Unfortunately, EGFR expression does not appear to
be predictive for response to EGFR inhibitors.14
Another mechanism for PI3/AKT pathway activation
is the loss of phosphatase and tensin homolog deleted on
chromosome 10 (PTEN), a tumor suppressor gene which
opposes PI3K/AKT activation.5,6 PTEN is the second most
mutated tumor suppressor gene after p53 and mutations
in PTEN are found in a variety of primary tumors includ-
ing HNSCC,7,15–18 while germline mutations in PTEN
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cause Cowden syndrome, characterized by hamartomas and
predisposition of breast and thyroid tumors.5,6 Besides the
role of PTEN in tumorigenesis as an antagonist in the
PI3K/AKT pathway, PTEN has also been associated with
genome stability including DNA double strand break (DSB)
repair by regulating the protein RAD51.15,19,20 Theoretically,
tumors with loss of function of PTEN are less able to repair
damage caused by radiotherapy. Furthermore, effect of
radiotherapy is based on the high proliferation rate of
tumors in relation to normal tissue. Consistent with this,
we previously found overexpression of PTEN was associ-
ated with increased radioresistance in a cohort of HNSCC
patients postoperatively treated with radiotherapy.19 The
present study was primary designed to evaluate this asso-
ciation and to establish the prognostic value of EGFR and
PTEN expression on local control in an independent well-
documented homogeneous series of early stage supragottic
LSCCs treated with radiotherapy only. We also evaluated
whether other clinicopathological characteristics were
associated with local control.
MATERIALS AND METHODS
Patients
The study population of the present study was composed of a
selected well-deﬁned homogenous group of patients with stage T1–
T2 histologically conﬁrmed squamous cell carcinoma of the sup-
raglottic larynx treated with radiotherapy with curative intent. This
study was restricted to this cohort of supraglottic tumors since previ-
ous studies showed differences in biological behavior between glottic
and supraglottic tumors.21 The same cohort of patients was described
in detail previously.21,22 Between 1990 and 2008, 1,286 patients were
diagnosedwith and/or treated for a laryngealmalignancy in our insti-
tute. Of all patients demographic and clinicopathological data such
as gender, age, T-status, and N-status were retrospectively collected
by reviewing the patient charts. The inclusion criteria for this study
were 1) histologically proven squamous cell carcinoma; 2) localized in
the supraglottic larynx; 3) staged cT1 and cT2; 4) with no evidence for
distant metastasis (cM0); 5) were curatively treated with radiother-
apy alone; and 6) received no other previous or concurrent treatment
modalities. In total, 247 patients with T1–T2 LSCCwere retrieved in
our database. Because of second primary tumors or previous chemo-
and/or radiotherapy, 10 patients were excluded. From this,
237 patients formalin-ﬁxed, parafﬁn-embedded pretreatment biop-
sies taken at our institute were collected and revised by an experi-
enced pathologist. Tissue specimens with sufﬁcient neoplastic cells
for immunohistochemical staining were available from 141 patients
of which 52 were supraglottic tumors. All data from the 52 patients
considered appropriate for immunohistochemistry after the exclu-
sionary process were retrieved and collected in an anonymous data-
base. All patients gave approval to use tissue samples for research.
Treatment
All patients were treated with primary radiotherapy as reported
previously.21,22 In short, in stage T1 tumors, a total dose of 66 Gy,
using 2 Gy fractions, ﬁve times weekly was given. Stage T2 tumors
were generally treated with six fractions weekly, to a total dose of
70 Gy within 6 weeks. In the case of elective radiotherapy to the neck
nodes, a total dose of 46 Gy was given to the primary planning target
volume, with an additional boost of 70 Gy to the primary tumor and
pathologic lymph nodes. In all patients, a planning-computed tomog-
raphy scan was made in supine position. The target volumes were
delineated as described in previous reports.23 All patients were treated
with 3D-conformal radiotherapy. After completion of treatment,
patients were followed at the outpatient clinic for 5 years.
Immunohistochemistry
EGFR and PTEN protein expression was respectively detected
using Novocastra monoclonal antibody clone 113 against EGFR
(Leica Biosystems, Newcastle, United Kingdom; Cat# NCL-L-EGFR,
RRID:AB_563696) and a monoclonal antibody clone 6H2.1 against
PTEN (Cascade BioScience, Winchester, United States; Cat# ABM-
2052, RRID:AB_2335636). Immunostaining was performed on 4 μm
parafﬁn sections. Antigen retrieval was achieved by heating in a
microwave in preheated Tris-HCL buffer (EGFR) and citrate buffer
(PTEN). Endogenous peroxidase was blocked by incubation with
0.3% hydrogen peroxidase for 30 minutes.
Slides were stained for 1 hour with the antibody against EGFR
(1:100) and PTEN (1:50). Secondary, rabbit anti-mouse antibody was
diluted1:100 in1%bovine serumalbumin inphosphate buffered saline
complemented with 1% human AB serum and applied for 30 minutes
at room temperature. Tertiary goat anti-rabbit antibody was diluted
1:100 and applied for 30 minutes at room temperature. Staining was
visualized with 3,30-diaminobenzidinetetrahydrochloride and counter-
stainedwithhematoxylin.
Evaluation of Immunostaining
Scoring was performed by two independent teams without
knowledge of clinical data. The discordant cases were reviewed and
scores were reassigned on consensus of opinion. For both antibodies,
staining intensity was semi-quantitatively scored as negative (−),
weak positive (+/−), positive (+), and strong positive (++). For
PTEN, the percentage of positive cells was scored as well. For
statistical analysis, any positive EGFR staining above back-
ground was considered as high (+/−, +, and ++).19 For PTEN,
tumors were considered high in case of >7.5% positive (+ or ++)
cytoplasmic staining.19
Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics
23 for Windows. Follow-up time was calculated from the day of diag-
nosis until the date of the last follow-up. Local recurrencewas deﬁned
as tumor recurrence at the primary tumor site within 5 years, and
was calculated from the date of diagnosis until the day of local recur-
rence or lost to follow-up. Relations (hazard ratio [HR] and 95% conﬁ-
dence interval [CI]) between recurrence and immunostaining and
other clinicopathological characteristics were calculated using uni-
variate Cox proportional hazard analysis and Kaplan–Meier analy-
sis. For multivariate Cox regression, only the variables that
appeared statistically signiﬁcant in univariate analysis were




The population showed a preference for the male
sex, T2, and lymph node negative tumors (for details, see
Table I). Almost all tumors showed high expression of
EGFR (92%). Thirteen (25%) patients had a high expres-
sion of PTEN with immunohistochemistry. In slides with
high expression for PTEN, the median percentage of posi-
tive neoplastic cells was 28% (range: 10–85).
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No Relation between EGFR Expression and Local
Control
Fourteen patients (26.9%) developed a local recurrence
after radiotherapy. Kaplan–Meier and Cox regression
analysis did not show a signiﬁcant relation between EGFR
expression and local control in our series of 52 supraglottic
laryngeal carcinomas (HR = 1.32, 95% CI = 1.17–10.14,
P = .79) (Table II and Fig. 1A).
PTEN Overexpression and Lymph Node Status
Are Associated with Local Control
In the population with high PTEN expression (n = 13),
seven patients (54%) developed a local recurrence, in contrast
to 18% in patients with low PTEN expression. Cox regression
revealed a signiﬁcant association betweenhighPTENexpres-
sion and local control (HR = 3.26, 95% CI = 1.14–9.33,
P= .027) (Table II and Fig. 1B).
In the population with positive lymph node status
(N+), 7 out of 13 patients (54%) had a local recurrence. In
the population with no lymph node metastasis, this per-
centage was 18%. Cox regression revealed a signiﬁcant
association between N+ and local control (HR = 3.60, 95%
CI = 1.26–10.31, P = .017) (Table II and Fig. 1C).
Multivariate Cox regression showed that high PTEN
expression and lymph node status were independent prog-
nostic factors in a multivariate analysis (HR = 3.28, 95%
CI = 1.14–9.39, P = .027 and HR = 3.62, 95% CI = 1.26–10.37,
P = .017, respectively) (Table III).
DISCUSSION
Previously, we reported that overexpression of PTEN
was associated with increased radioresistance in a cohort
of HNSCC patients postoperatively treated with radio-
therapy.19 In this study, we evaluated the prognostic
value of PTEN expression on local control in an indepen-
dent well-documented homogeneous series of early stage
supragottic LSCCs all treated curatively with radiother-
apy only. In this homogeneous cohort of 52 patients, a sig-
niﬁcant association between PTEN expression and local
control was observed.
The last decade the PI3K/AKT signaling pathway
has become an important target in cancer therapy includ-
ing HNSCC with the use of cetuximab, an anti-EGFR
antibody applied in advanced nonmetastatic HNSCC in
combination with radiotherapy or as a single agent in
patients who have had prior platinum-based therapy.13
EGFR status as a speciﬁc predictive marker for response
to EGFR inhibitors is controversial.14 Numerous studies
reported on the prognostic value of immunohistochemical
EGFR expression in different tumor types.10,19,24 In our
homogeneous cohort consisting of early stage supraglottic
LSCCs treated with radiotherapy alone, no signiﬁcant
relationship between EGFR expression and local control
was found. Conﬂicting results have been published earlier
concerning EGFR overexpression and association with
local control in HNSCC. For instance, Ang et al reported
worse local control and overall survival in a group of
155 advanced HNSCCs treated with radiation therapy
overexpressing EGFR.10 In contrast, Eriksen et al failed
to show a signiﬁcant relationship between EGFR over-
expression and local control in a group of 336 HNSCCs
treated with conventional or accelerated radiation ther-
apy.24 There are different reasons for these conﬂicting
TABLE I.
Patient and Tumor Characteristics of All Patients (n = 52).
Characteristics No. of Patients (%)
Age—years
















EGFR = epidermal growth factor receptor; N = node; PTEN = phospha-
tase and tensin homolog deleted on chromosome 10; T = tumor.
TABLE II.
Patient Characteristics, Tumor Characteristics, EGFR Expression
and PTEN Expression in Relation to Local Recurrence (n = 14).
Characteristics
No. of Patients
with Local Recurrence (%)
Univariate
HR (95% CI) P
Age—years
<65 8/32 (25.0) 1
≥65 6/20 (30.0) 1.51 (0.52–4.36) .45
Gender
Female 2/11 (18.2) 1
Male 12/41 (29.3) 1.81 (0.40–8.09) .44
cT-stadium
T1 3/15 (20.0) 1
T2 11/37 (29.7) 1.63 (0.46–5.86) .45
cN-stadium
N0 7/39 (17.9) 1
N+ 7/13 (53.8) 3.60 (1.26–10.31) .017*
EGFR
Low 1/4 (25.0) 1.32 (1.17–10.14) .79
High 13/48 (27.1) 1
PTEN
Low 7/39 (17.9) 1
High 7/13 (53.8) 3.26 (1.14–9.33) .027*
*Signiﬁes statistically signiﬁcant relation.
CI = conﬁdence interval; EGFR = epidermal growth factor receptor;
HR = hazard ratio; N = node; PTEN = phosphatase and tensin homolog
deleted on chromosome 10; T = tumor.
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results. First, the prognostic signiﬁcance of EGFR has
been investigated in heterogeneous HNSCC populations
treated with different treatment modalities. Second, there
is no general consensus regarding the staining protocols
and scoring methods of EGFR.19 The interpretation of the
results in our study is difﬁcult since there were only four
cases with low EGFR expression. Compared to other
studies on EGFR expression in HNSCC, we found a high
percentage of high EGFR cases (92%) versus 53%–88% in
HNSSC described in literature.19,24–28 There is only one
other study concerning EGFR expression in supraglottic
laryngeal carcinomas, showing high EGFR expression in
83% and 70% of T1 and T2 tumors, respectively.25 How-
ever, they used a different primary antibody and scoring
criteria, which makes it difﬁcult to compare. We also per-
formed EGFR immunostaining on a well-deﬁned series of
early stage (T1–T2) glottic LSCCs treated with radiother-
apy only and found signiﬁcantly more tumors in the
Fig. 1. Kaplan–Meier curves for the relation of EGFR expression (A), PTEN expression (B), and lymph node (N) status (C) with local control.
EGFR = epidermal growth factor receptor; PTEN = phosphatase and tensin homolog deleted on chromosome 10.
TABLE III.
Results of Multivariate Cox Regression Analysis for Local Control.
Characteristics Multivariate HR (95% CI) P
N+ 3.62 (1.26–10.37) 0.017*
High PTEN 3.28 (1.14–9.39) 0.027*
*Signiﬁes statistically signiﬁcant relation.
CI = conﬁdence interval; HR = hazard ratio; N = node; PTEN = phos-
phatase and tensin homolog deleted on chromosome 10.
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supraglottic group with high EGFR expression compared to
the glottic group (92% vs. 53%) (Wachters et al, unpublished
data). This suggests also an association between EGFR
expression levels and different tumor locations and supports
our decision to restrict our analysis to a homogeneous series
of supraglottic LSCCs only.
Besides activation of EGFR, another mechanism for
PI3/AKT pathway activation is the loss of PTEN expres-
sion. Previously, PTEN expression has been linked to
therapeutic outcome in HNSCC.19,29–31 In this study, we
showed a signiﬁcant relation between high PTEN expres-
sion and worse local control. Low PTEN expression by
immunostaining was observed in 75% of patients similar
as we observed earlier in HNSCC.19 Lower percentages of
33%–56% using the same antibody were reported as
well,32,33 in which supraglottic LSCC appeared to has less
often loss of expression than glottic LSCC.33 This is possi-
bly explained by the more often raised disease of sup-
raglottic LSCC.33 This percentages are corresponding to
mutations and loss of heterozygosity of PTEN gene found
in 23%–33% and 10%–40% of HNSCC, respectively.16–18
However, a study in non-small cell lung cancer showed
that neither methylation nor loss of heterozygosity was a
signiﬁcant predictor of PTEN protein expression with
immunohistochemistry.34 Among several types of com-
mercially available PTEN monoclonal antibodies, PTEN
monoclonal antibody clone 6.H2.1 was the only one asso-
ciated with PTEN molecular alterations.35
The results of this study conﬁrmed previously found
relation between high expression of PTEN and worse local
control in a series of squamous cell carcinomas of the lar-
ynx, hypopharynx, oropharynx, and oral cavity treated with
primary surgery and postoperative radiotherapy.19 The
explanation for this association was that PTEN functions in
DSB repair.20 Cells have evolved several protective re-
sponses to counteract the harmful effects of DNA-damage
including homologous recombination and nonhomologous
end-joining for DSB. Homologous recombination ensures
accurate DSB-repair mediated through the so called RAD52
group of proteins which includes RAD51. RAD51 is regulated
by PTEN.15,19,20 We speculate that tumors with low function
of PTEN are less able to repair damage caused by radiother-
apy. Other studies on PTEN expression in relation with
prognosis in HNSCC have linked, on the contrary, low
PTEN to worse prognosis of disease in both surgery and
radiotherapy.29–31 An explanation for this observation is
the counteracting function of PTEN on the PI3K/AKT anti-
apoptotic and proliferation pathway that could contribute
to tumorigenesis and worse prognosis.5,6Positive lymph
node status was associated with the development of local
recurrence. This was an unexpected outcome because re-
gional metastasis is not a known risk factor for developing
local recurrence and suggests the higher aggressiveness of
these tumors in general. It was not in relationwith tumor size
because there was no difference in outcome between T1 and
T2 tumors. The relation of regional metastasis and deterio-
rated local control should be evaluated in larger series of early
stage supraglottic LSCC.
This study was weakened by its small series of only
52 patients. On the other hand, the great strength of this
study was the composition of a well-deﬁned homogeneous
cohort consisting of supraglottic LSCCs treated with
radiotherapy alone. The relevance to distinguish between
supraglottic and glottic LSCC evaluating (prognostic) immu-
nohistochemical expression of antibodies has become clear
fromprevious studies.21,22,33,36 Althoughwe performedEGFR
immunostaining on a series of early stage glottic LSCC as
well, wedidnot performPTEN immunostaining on this glottic
LSCC series. It was quite difﬁcult to obtain a useful immuno-
histochemical visualization of PTEN on the supraglottic
LSCC biopsies. Therefore, we decided not to sacriﬁce the
mostly small biopsies from the glottic LSCC patients. One of
the reasons for radioresistance in HNSCC is accelerated
repopulation of tumor cells after exposure to ionizing radia-
tion.9,24,25,37 One of the mechanisms contributing to this
repopulation is activation of the EGFR/PI3K/AKT pathway.
Binding of cetuximab to theEGF receptor leads to internaliza-
tion and degradation of the antibody-receptor complex, down-
regulating EGFR expression.9,38 In SCC cell lines, Bonner
et al showed that the combination of cetuximab and radiation
resulted in decreased cellular proliferation.39 Bonner et al
showed that among patients with stage III–IV HNSCC, the
addition of cetuximab to radiotherapy resulted in a signiﬁcant
improvement of locoregional control and survival as compared
to radiotherapy alone, without enhancing radiation-induced
toxicity.40,41 Based on the results of this study, cetuximab is
now increasingly used in combination with deﬁnitive radio-
therapy in locally advanced disease in particular for patients
in which concurrent chemoradiation is considered not feasi-
ble. So far, no studies have been published which compared
concomitant cetuximab and radiotherapy in combinationwith
EGFR levels in early stage laryngeal carcinoma.
This study showed a potential role in diagnostic and
prognostic terms for PTEN immunohistochemical evalua-
tion in supraglottic LSCC in which patients with sup-
raglottic LSCC with a high PTEN immunohistochemical
expression might beneﬁt from altered radiotherapy sched-
ules or additional PTEN inhibiting drugs. Because of the
antagonize behavior of PTEN on the P13/AKT pathway,
most of the strategies to target PTEN are focused on
PTEN-deﬁcient cancers utilize inhibitors of kinases that
lie at the level of PI3K/AKT pathway.42 Furthermore, due
to the activation of the EGFR/P13/AKT pathway, PTEN
inactivation could theoretically lead to resistance to
EGFR inhibitors. Frattini et al showed in a series of colo-
rectal cancer patients that loss of PTEN expression by
immunohistochemistry distinguished responder from
nonresponder patients to cetuximab.43 Studies in prostate
cancer cells showed a comparable relation and PTEN
reintroduction restored the cell response to cetuximab.44
This supports the suggestion that supraglottic LSCC
patients with high PTEN expression might beneﬁt from
adding cetuximab to radiotherapy.
CONCLUSION
This study conﬁrmed earlier found association between
high PTEN expression and local control in HNSCC. The
worse local control found in cases with high PTEN expres-
sion might suggest the importance of PI3K-AKT indepen-
dent functions of PTEN such as DNA-damage repair in
radioresponse. PTEN status could have an additive value in
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determining the prognosis of early stage supraglottic laryn-
geal carcinomas, next to the already used clinical factors as
lymph node status. These patients might beneﬁt from an
alternated radiation schedule, drugs interfering with DNA-
damage repair, or adding cetuximab.
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